Apixaban

Tlhaloso e Khutšoanyane:

Lebitso la API Pontsho Tlhaloso US DMF EU DMF CEP
Apixaban VTE Ka Ntlong


Lintlha tsa Sehlahisoa

Li-tag tsa Sehlahisoa

TLHAKISO SEHLAHISO

Ka morao

Apixaban ke inhibitor e khethang haholo ebile e fetoleloa morao ea Factor Xa e nang le boleng ba Ki ea 0.08 nM le 0.17 nM ho motho le mmutla, ka ho latellana[1].

Factor X, eo hape e tsejoang ka eponym Stuart-Prower factor, ke enzyme ea coagulation cascade.Factor X e sebelisoa, ka hydrolysis, ho factor Xa ka bobeli factor IX.Factor Xa is the activated form of the coagulation factorthrombokinase.Inhibiting Factor Xa e ka fana ka mokhoa o mong oa anticoagulation.Li-inhibitors tsa Direct Xa ke li-anticoagulants tse tsebahalang [2].

In vitro: Apixabanhas e bontšitse tekanyo e phahameng ea potency, selectivity, le katleho ho Factor Xa le Ki ea 0.08 nM le 0.17 nM bakeng sa Human Factor Xa le Rabbit Factor Xa, ka ho latellana [1].Apixaban e lelefatsa nako ea ho koala ha plasma e tloaelehileng ea motho ka li-concents (EC2x) tsa 3.6, 0.37, 7.4 le 0.4 μM, tse hlokehang ka ho latellana ho habeli nako ea prothrombin (PT), nako e fetotsoeng ea prothrombin (mPT), e entsoeng ka nako e itseng ea thromboplastin ( APTT) le HepTest.Ntle ho moo, Apixaban e bontšitse matla a phahameng ka ho fetisisa ho plasma ea batho le ea mmutla, empa matla a fokolang a plasma ea likhoto le lintja litlhahlobong tsa PT le APTT [3].

In vivo: Apixaban e hlahisitse pharmacokinetics e ntle ka ho fetisisa e nang le tumello e tlaase haholo (Cl: 0.02 L kg-1h-1), le palo e tlaase ea kabo (Vdss: 0.2 L / kg) ho ntja.Ntle ho moo, Apixaban e boetse e bonts'a halofo ea bophelo bo itekanetseng le T1 / 2 ea lihora tsa 5.8 le bioavailability e ntle ea molomo (F: 58%) [1].Ka har'a arteriovenous-shunt thrombosis (AVST), venous thrombosis (VT) le mefuta ea meutlanyana ea carotid arterial thrombosis (ECAT), Apixaban e hlahisitse litlamorao tsa antithrombotic ka EC50 ea 270 nM, 110 nM le 70 nM ka mokhoa o itšetlehileng ka lethal dose [3. ].Apixaban e thibelitse haholo ts'ebetso ea Xa ka IC50 ea 0.22 μM ho mmutla ex vivo[4].Ka lichimpanzi, Apixaban o ile a boela a bontša palo e nyenyane ea ho aba (Vdss: 0.17 L kg-1), tumello e tlaase ea tsamaiso (Cl: 0.018 L kg-1h-1), le bioavailability e ntle ea molomo (F: 59%) [5].

Litšupiso:
Pinto DJP, Orwat MJ, Koch S, et al.Ho sibolloa ha 1-(4-methoxyphenyl) -7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl) -4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4- c] pyridine-3-carboxamide (Apixaban, BMS-562247), e matla haholo, e khethang, e sebetsang hantle, le ea molomo ea bioavailable inhibitor ea mali a coagulation factor Xa[J].Journal of chemistry ea meriana, 2007, 50 (22): 5339-5356.
Sidhu P S. Direct Factor Xa Inhibitors e le Anticoagulants[J].
Wong PC, Crain EJ, Xin B, et al.Apixaban, oral, e tobileng le e khethehileng haholo ea Xa inhibitor: in vitro, antithrombotic le antihemostaticstudies[J].Journal of Thrombosis le Haemostasis, 2008, 6 (5): 820-829.
Zhang D, He K, Raghavan N, et al.Metabolism, pharmacokinetics le pharmacodynamics ea factor Xa inhibitor apixaban ka mebutlanyana[J].Journal of thrombosis le thrombolysis, 2010, 29 (1): 70-80.
He K, Luettgen JM, Zhang D, et al.Preclinical pharmacokinetics le pharmacodynamics ea apixaban, e matla le e khethang factor Xa inhibitor[J].Koranta ea Europe ea metabolism ea lithethefatsi le pharmacokinetics, 2011, 36 (3): 129-139.

Apixaban ke inhibitor e khethang haholo ebile e fetoleloa morao ea Factor Xa e nang le boleng ba Ki ea 0.08 nM le 0.17 nM ho motho le mmutla, ka ho latellana[1].

Factor X, eo hape e tsejoang ka eponym Stuart-Prower factor, ke enzyme ea coagulation cascade.Factor X e sebelisoa, ka hydrolysis, ho factor Xa ka bobeli factor IX.Factor Xa is the activated form of the coagulation factorthrombokinase.Inhibiting Factor Xa e ka fana ka mokhoa o mong oa anticoagulation.Li-inhibitors tsa Direct Xa ke li-anticoagulants tse tsebahalang [2].

In vitro: Apixabanhas e bontšitse tekanyo e phahameng ea potency, selectivity, le katleho ho Factor Xa le Ki ea 0.08 nM le 0.17 nM bakeng sa Human Factor Xa le Rabbit Factor Xa, ka ho latellana [1].Apixaban e lelefatsa nako ea ho koala ha plasma e tloaelehileng ea motho ka li-concents (EC2x) tsa 3.6, 0.37, 7.4 le 0.4 μM, tse hlokehang ka ho latellana ho habeli nako ea prothrombin (PT), nako e fetotsoeng ea prothrombin (mPT), e entsoeng ka nako e itseng ea thromboplastin ( APTT) le HepTest.Ntle ho moo, Apixaban e bontšitse matla a phahameng ka ho fetisisa ho plasma ea batho le ea mmutla, empa matla a fokolang a plasma ea likhoto le lintja litlhahlobong tsa PT le APTT [3].

In vivo: Apixaban e hlahisitse pharmacokinetics e ntle ka ho fetisisa e nang le tumello e tlaase haholo (Cl: 0.02 L kg-1h-1), le palo e tlaase ea kabo (Vdss: 0.2 L / kg) ho ntja.Ntle ho moo, Apixaban e boetse e bonts'a halofo ea bophelo bo itekanetseng le T1 / 2 ea lihora tsa 5.8 le bioavailability e ntle ea molomo (F: 58%) [1].Ka har'a arteriovenous-shunt thrombosis (AVST), venous thrombosis (VT) le mefuta ea meutlanyana ea carotid arterial thrombosis (ECAT), Apixaban e hlahisitse litlamorao tsa antithrombotic ka EC50 ea 270 nM, 110 nM le 70 nM ka mokhoa o itšetlehileng ka lethal dose [3. ].Apixaban e thibelitse haholo ts'ebetso ea Xa ka IC50 ea 0.22 μM ho mmutla ex vivo[4].Ka lichimpanzi, Apixaban o ile a boela a bontša palo e nyenyane ea ho aba (Vdss: 0.17 L kg-1), tumello e tlaase ea tsamaiso (Cl: 0.018 L kg-1h-1), le bioavailability e ntle ea molomo (F: 59%) [5].

Litšupiso:
Pinto DJP, Orwat MJ, Koch S, et al.Ho sibolloa ha 1-(4-methoxyphenyl) -7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl) -4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4- c] pyridine-3-carboxamide (Apixaban, BMS-562247), e matla haholo, e khethang, e sebetsang hantle, le ea molomo ea bioavailable inhibitor ea mali a coagulation factor Xa[J].Journal of chemistry ea meriana, 2007, 50 (22): 5339-5356.
Sidhu P S. Direct Factor Xa Inhibitors e le Anticoagulants[J].
Wong PC, Crain EJ, Xin B, et al.Apixaban, oral, e tobileng le e khethehileng haholo ea Xa inhibitor: in vitro, antithrombotic le antihemostaticstudies[J].Journal of Thrombosis le Haemostasis, 2008, 6 (5): 820-829.
Zhang D, He K, Raghavan N, et al.Metabolism, pharmacokinetics le pharmacodynamics ea factor Xa inhibitor apixaban ka mebutlanyana[J].Journal of thrombosis le thrombolysis, 2010, 29 (1): 70-80.
He K, Luettgen JM, Zhang D, et al.Preclinical pharmacokinetics le pharmacodynamics ea apixaban, e matla le e khethang factor Xa inhibitor[J].Koranta ea Europe ea metabolism ea lithethefatsi le pharmacokinetics, 2011, 36 (3): 129-139.

Sebopeho sa lik'hemik'hale

Apixaban

TSAMAISO KHABANE

Quality management1

Tlhahiso18Merero ea Tlhahlobo ea Boleng e amohetsoeng4, le6merero e tlas'a tumello.

Quality management2

Sistimi e tsoetseng pele ea boleng ba machaba e thehile motheo o tiileng oa thekiso.

Quality management3

Tlhokomelo ea boleng e tsamaisana le potoloho eohle ea bophelo ba sehlahisoa ho netefatsa boleng le phello ea kalafo.

Quality management4

Sehlopha sa Litaba tsa Taolo ea Setsebi se tšehetsa litlhoko tsa boleng nakong ea kopo le ngoliso.

TS'ELISO TS'OANELO

cpf5
cpf6

Korea Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italy CAM Board Packaging Line

cpf11

Mochini oa Sejeremane oa Fette Compacting

cpf12

Japan Viswill Tablet Detector

cpf14-1

Kamore ea ho laola ea DCS

MOTHOANA

Tšebelisano ea machaba
International cooperation
Tšebelisano 'moho ka lapeng
Domestic cooperation

  • E fetileng:
  • E 'ngoe:

  • Ngola molaetsa wa hao mona mme o re romele wona

    Lihlopha tsa lihlahisoa